Dr. Yap specializes in the management of urologic cancers (kidney, bladder, prostate, and testes). His practice includes open, minimally invasive and robotic surgical approaches. He believes in a collaborative and personalized approach to provide the best possible care to each of his patients.
Dr. Yap's research interests include the development and evaluation of new diagnostic and treatment strategies in the management of all urologic malignancies.
He is also interested in assessing the quality of care and the effectiveness of our treatments to provide the most efficient care for patients.
UC Davis Comprehensive Cancer Center
2279 45th Street, 2nd Floor
Sacramento, CA 95817
M.Sc., Clinical Epidemiology, University of Toronto, Toronto, ON Canada 2013
B.S., University of Michigan, Ann Arbor MI 2000
General Surgery, UC Davis Medical Center, Sacramento CA 2004-2006
Chief Resident Urologic Surgery, UC Davis Medical Center, Sacramento CA 2009-2010
Royal College of Physicians of Canada,
American Urologic Association
Canadian Urologic Association
Society of Urologic Oncology
Select Honors and Awards:
Pillsbury Award-Most Distinguished Undergraduate Dissertation in Psychology, University of Michigan, 2000
Earl F. Nation Resident Scholarship (Western section AUA), 2007
Earl F. Nation Resident Scholarship (Western section AUA), 2008
N. California Urological Resident Research Seminar - First place - Basic science, 2009
Gerald P. Murphy Memorial Scholar (AUA), 2009
Charles J. Robson Research Day (Toronto, ON, Canada) - Second place - clinical research, 2011
Amgen Canada Fellowship (AUA), 2011
Health Policy, Management, and Evaluation Research Day - First place poster - health services research, 2011
Canadian Urologic Association Meeting – Five-star poster award - general oncology, 2011
Resident Teaching Award, University of Toronto, 2013
Select Recent Publications:
Yap SA. Should we worry about positive surgical margins in prostate cancer? BJU Int. 2016 Feb;117(2):207-8.
Yap SA. Quantifying patient care: What metrics do we use? Can Urol Assoc J. 2015 Mar-Apr;9(3-4):E228-9. doi: 10.5489/cuaj.2875.
Mooso BA, Vinall RL, Mudryj M, Yap SA, deVere White RW, Ghosh PM. The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence. J Urol. 2015 Jan;193(1):19-29.
Yap SA, Finelli A, Urbach DR, Tomlinson GA, Alibhai SM. Partial nephrectomy for the treatment of renal cell carcinoma (RCC) and the risk of end-stage renal disease (ESRD). BJU Int. 2015 Jun;115(6):897-906.
Yap SA, Alibhai SM, Margel D, Abouassaly R, Timilshina N, Finelli A. A population-based study of surgeon characteristics associated with the uptake of contemporary techniques in renal surgery. Can Urol Assoc J. 2013 Sep-Oct;7(9-10):E576-81.
Yap SA, Finelli A, Alibhai SM. Treating small renal masses: Costing it out. Can Urol Assoc J. 2013 Mar-Apr;7(3-4):114-5.
Yap SA, Alibhai SM, Abouassaly R, Timilshina N, Margel D, Finelli A. Ipsilateral adrenalectomy at the time of radical nephrectomy impacts overall survival. BJU Int. 2013 Mar;111(3 Pt B):E54-8.
Margel D, Yap SA, Lawrentschuk N, Klotz L, Haider M, Hersey K, Finelli A, Zlotta A, Trachtenberg J, and Fleshner N. Impact of multiparametric endorectal coil prostate MRI on disease reclassification among active surveillance candidates - a prospective cohort study. J Urol. 2012, Apr, 187(4): 1247-52.
Yap SA, Horovitz D, Alibhai SM, Abouassaly R, Timilshina N, Finelli A. Predictors of early mortality after radical nephrectomy with renal vein or inferior vena cava thrombectomy - a population-based study. BJU Int. 2012 Nov;110(9):1283-8.